<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057499</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN012AI</org_study_id>
    <secondary_id>DAIT BD012</secondary_id>
    <nct_id>NCT00057499</nct_id>
  </id_info>
  <brief_title>Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics</brief_title>
  <official_title>Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin dependent diabetes mellitus (also called type 1 diabetes mellitus or T1DM) is caused
      by the destruction of insulin-producing cells in the pancreas. People with T1DM do not
      produce enough insulin, which is necessary for proper regulation of blood sugar levels.

      T1DM is an autoimmune disease. An autoimmune disease is a disease in which the body's immune
      system attacks the body itself. In addition to regulating blood sugar, insulin may have the
      ability to protect cells in the pancreas from attack by the immune system. This study will
      evaluate whether an insulin-based vaccine can protect cells from autoimmune destruction.

      Study hypothesis: IFA-enhanced human insulin B-chain vaccination will lead to the arrest or
      slowing of the ongoing autoimmunity, and this will result in an appreciable difference in
      functioning B cell mass compared to the placebo treated group by the end of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine in this study, IBC-VSO1, is a synthetic, metabolically inactive form of insulin
      designed to prevent pancreatic beta-cell destruction. It does not cause fluctuations in blood
      sugar. This study will evaluate whether the vaccine protects against autoimmune attack at the
      onset of T1DM, before pancreas function has deteriorated. This experimental treatment must
      occur early because 60% to 85% of beta-cells are already destroyed by the time of T1DM
      diagnosis. If beta-cell destruction can be halted, a prolonged remission period after
      diagnosis may occur, with a subsequent delay in diabetes-related complications.

      Participants must have been diagnosed with T1DM for no more than 3 months at the time of
      enrollment in this study. Participants will be randomly assigned to either a vaccine group or
      a control group. Participants in the vaccine group will receive one injection of IBC-VS01;
      participants in the control group will receive a placebo. Participants will then be monitored
      for 2 years. Participants will have ten follow-up visits, which will include blood tests for
      immunological and genetic analysis. Throughout the study, metabolic tests will also be
      performed to measure the remaining capacity of self insulin production of the body.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide levels in response to mixed meal tolerance test</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c, GAD65Ab, IAA, IA2Ab, GAD65Ab isotypes</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4- and CD8- Va24JaQ+</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cells' secretion of IL-4 and Interferon (IFN)-gamma</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Insulin-dependent Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>IBC-VS01 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBC-VS01 vaccine is administered twice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IBC-VS01 placebo is administered twice</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBC-VS01</intervention_name>
    <description>IBC-VS01</description>
    <arm_group_label>IBC-VS01 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBC-VS01 placebo</intervention_name>
    <description>IBC-VS01 placebo</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 1 diabetes mellitus within 3 months prior to study entry

          -  Positive for IAA, GAD65, or IA2 antibodies OR positive for GAD65 or IA2 antibodies
             after 2 weeks of starting insulin treatment

        Exclusion Criteria:

          -  History of treatment with any oral hypoglycemic agent for more than 3 months

          -  Ongoing use of medications known to influence glucose tolerance

          -  History of immunosuppressive or steroid therapy for more than 3 months within the 2
             years prior to study entry

          -  Severe active liver, heart, kidney, or immunodeficiency disease that may limit life
             expectancy or may require immunosuppression during the study

          -  Prior complications related to routine vaccinations

          -  Prior participation in a trial for prevention of type 1 diabetes mellitus. Individuals
             who are known to have been in the placebo arm of a completed prevention trial are not
             excluded.

          -  Any condition that may interfere with a participant's ability to comply with the study

          -  Pregnancy or planned pregnancy within the time frame of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tihamer Orban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network (ITN) website</description>
  </link>
  <results_reference>
    <citation>Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010 Jun;34(4):408-15. doi: 10.1016/j.jaut.2009.10.005.</citation>
    <PMID>19931408</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2003</study_first_submitted>
  <study_first_submitted_qc>April 3, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2003</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Juvenile diabetes</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data access is provided to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) portal.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>SDY568</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY568</doc_url>
      <doc_comment>ImmPort study identifier is SDY568.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY568</doc_id>
      <doc_type>Study summary, -schematic, -design, medications,-demographics, - lab tests, -study files</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY568</doc_url>
      <doc_comment>ImmPort study identifier is SDY568.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN012AI</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN012AIPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is the Immune Tolerance Network (ITN) portal that makes data from the consortium's clinical trials publicly available without charge. Creating an account for ITN TrialShare is free and allows for searching studies of interest.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN012AI</doc_id>
      <doc_type>Study protocol synopsis, -navigator, -schedule of events,-data &amp;reports, -specimens et al.</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN012AIPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is the Immune Tolerance Network (ITN) portal that makes data from the consortium's clinical trials publicly available without charge. Creating an account for ITN TrialShare is free and allows for searching studies of interest.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

